Source:http://linkedlifedata.com/resource/pubmed/id/11867945
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
2002-2-27
|
| pubmed:abstractText |
Left ventricular hypertrophy (LVH) commonly occurs in patients with end-stage renal disease (ESRD) and is an independent risk factor for cardiovascular events. Angiotensin II type 1 receptor (AT1-R) antagonists may be able to reverse LVH independent to the hypotensive effect in the ESRD setting. Thirty chronically hemodialyzed uremic patients with hypertension were randomly assigned to receive the AT1-R antagonist losartan (n = 10), the angiotensin-converting enzyme (ACD) inhibitor enalapril (n = 10), or calcium antagonist amlodipine (n = 10). Left ventricular mass (LVM) index was measured by echocardiography before and 6 months after treatment. The baseline demographic and clinical characteristics did not differ between the three groups. The mean baseline LVM index also did not differ in the three groups. After 6 months of treatment, losartan treatment significantly reduced the LVM index (-24.7 +/- 3.2%) than amlodipine (-10.5 +/- 5.2%) or enalapril (-11.2 +/- 4.1%) therapy. All three groups had a similar decrease in the mean blood pressure with treatment. The plasma angiotensin II concentration increased 5-fold with losartan treatment. In contrast, the plasma angiotension II concentration did not change with enalapril and only increased 2-fold with amlodipine. Thus, the present study indicates that losartan more effectively regresses LVH in patients with ESRD than do enalapril and amlodipine despite a comparable depressor effect between the three drugs.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Amlodipine,
http://linkedlifedata.com/resource/pubmed/chemical/Angiotensin II,
http://linkedlifedata.com/resource/pubmed/chemical/Angiotensin Receptor Antagonists,
http://linkedlifedata.com/resource/pubmed/chemical/Antihypertensive Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Enalapril,
http://linkedlifedata.com/resource/pubmed/chemical/Losartan,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, Angiotensin, Type 1
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Mar
|
| pubmed:issn |
0028-2766
|
| pubmed:author | |
| pubmed:copyrightInfo |
Copyright 2002 S. Karger AG, Basel
|
| pubmed:issnType |
Print
|
| pubmed:volume |
90
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
256-61
|
| pubmed:dateRevised |
2010-11-18
|
| pubmed:meshHeading |
pubmed-meshheading:11867945-Adult,
pubmed-meshheading:11867945-Aged,
pubmed-meshheading:11867945-Aged, 80 and over,
pubmed-meshheading:11867945-Amlodipine,
pubmed-meshheading:11867945-Angiotensin II,
pubmed-meshheading:11867945-Angiotensin Receptor Antagonists,
pubmed-meshheading:11867945-Antihypertensive Agents,
pubmed-meshheading:11867945-Echocardiography,
pubmed-meshheading:11867945-Enalapril,
pubmed-meshheading:11867945-Female,
pubmed-meshheading:11867945-Heart Ventricles,
pubmed-meshheading:11867945-Humans,
pubmed-meshheading:11867945-Hypertension,
pubmed-meshheading:11867945-Hypertrophy, Left Ventricular,
pubmed-meshheading:11867945-Kidney Failure, Chronic,
pubmed-meshheading:11867945-Losartan,
pubmed-meshheading:11867945-Male,
pubmed-meshheading:11867945-Middle Aged,
pubmed-meshheading:11867945-Receptor, Angiotensin, Type 1,
pubmed-meshheading:11867945-Renal Dialysis
|
| pubmed:year |
2002
|
| pubmed:articleTitle |
Angiotensin II type 1 receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal disease.
|
| pubmed:affiliation |
Department of Medicine II, Kansai Medical University, Moriguchi, Osaka, Japan.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|